COMPARISON OF SAFETY AND EFFICACY OF THE COMBINATION PRODUCT QVA149A AGAINST THE CONCURRENT ADMINISTRATION OF THE INDIVIDUAL COMPONENTS, QAB149 AND NVA237, IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD):